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Objectives: The aim of this study was to investigate the long-term clinical and
hemodynamic outcomes after aortic valve replacement with the Carpentier-Edwards
Perimount bioprosthesis (Edwards Lifesciences, Irvine, Calif), which has been used
in our institution since 1984.
Methods: From January 1984 to December 1995, the Carpentier-Edwards pericar-
dial bioprosthesis was used for aortic valve replacement in 254 patients (male/
female ratio 117:137) with a mean age of 71 years (range 25-87 years). Before the
operation, 216 patients (85%) were in New York Heart Association functional class
III or IV. The predominant diagnosis was aortic stenosis (n 219, 86%). Associated
surgical procedures included coronary artery bypass grafting in 130 cases (51%),
mitral valve replacement in 11 cases (4%), and tricuspid or mitral valve repair in 12
cases (5%). Previous cardiac operations had been performed in 36 cases (14%).
Follow-up was 100% complete at a mean of 60  31 months. Univariate estimates
of time-related cumulative probabilities were calculated by the Kaplan-Meier
method. Multivariable adjustment was performed by Cox proportional hazards
regression. Echocardiography was performed in 61% of long-term survivors.
Results: There were 11 early deaths (4%) and 58 late deaths. Actuarial survivals at
5, 10, and 12 years were 80%  3%, 50%  8%, and 36%  9%, respectively. At
12 years the freedom from cardiac death was 73%  7%, the freedom from
valve-related death was 84%  11%, the freedom from valve reoperation was 83%
 9%, the freedom from primary tissue failure was 86%  9%, the freedom from
thromboembolism was 67% 13%, and the freedom from endocarditis was 98%
1%. Echocardiography was performed on long-term survivors (mean follow-up
67  25 months) and showed that transvalvular peak and mean pressure differences
measured with Doppler echocardiography were 23.2  9.6 and 12.3  4.8 mm Hg,
respectively. Aortic regurgitation was found by Doppler echocardiography to be
none or trivial, mild, moderate, and severe in 64%, 30%, 3%, and 1% of patients,
respectively. Mean left ventricular mass index was 107.2 35.3 g/m2 (118.9 40.2
g/m2 in men and 98.8  28.8 g/m2 in women) at late follow-up. One third of all
patients, regardless of sex (n  26/64 women and n  14/45 men), had evidence of
left ventricular hypertrophy. However, our analyses indicate that the residual left
ventricular hypertrophy was not caused by valve mismatch but was probably
multifactorial.
Conclusion: The Carpentier-Edwards Perimount bioprosthesis has provided satis-
factory clinical and hemodynamic outcome. However, at long-term follow-up about
one third of the patients being investigated still had left ventricular hypertrophy
examined by echocardiography.
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The Carpentier-Edwards Perimount (CEP)bioprosthesis (Edwards Lifesciences, Irvine,Calif) has been in clinical use since 1980 inCanada. We began using it in 1984. Thelong-term clinical results have previouslybeen reported to be excellent, and this valve
is regarded the bioprosthesis of choice by many surgeons.1-4
This study reviews our experience with the CEP biopros-
thesis and also examines its late hemodynamic perfor-
mance.
Material and Methods
Patients
From January 1984 to December 1995 the CEP pericardial bio-
prosthesis (model 2900; Edwards Lifesciences, Irvine, Calif) was
used for aortic valve replacement (AVR) in 254 patients with a
mean age of 71 years (range 25-87 years). The clinical profile and
the operative data of these patients are summarized in Tables 1 and
2, respectively.
From 1984 to 1989, all patients undergoing valve replacement
with the CEP were discharged from the hospital with a regimen of
daily warfarin sodium for the first 3 months after the operation,
followed by lifelong aspirin therapy. This practice was changed in
1990, after which patients were discharged with a regimen of
lifelong aspirin therapy only, with the exception of those in need
of warfarin sodium for other indications, such as chronic atrial
fibrillation or a concomitant mitral valve procedure.
Operative survivors were followed up by telephone or ques-
tionnaire between October 1998 and January 1999. The follow-up
was 100% complete. The mean follow-up was 60  31 months
(range 1-167 months), and 1214 patient-years of follow-up were
available for analysis.
Doppler Echocardiography
Transthoracic echocardiography with continuous-wave, pulsed-
wave, and color flow Doppler studies were performed with a
Hewlett Packard 1000, 1500, 2500, or 5500 Ultrasonoscope
(Hewlett-Packard Company, Palo Alto, Calif) equipped with a
2.5-MHz transducer. Sixty-one percent of survivors (n 109/178)
had an echocardiogram performed at our hospital between Decem-
ber 1998 and May 1999. The mean follow-up for these studies was
67 25 months (range 7-172 months). Those patients who did not
undergo echocardiography either lived too far away from the
hospital or were too old and in too fragile a condition to come
without great difficulty.
For further details about measurements and calculations, see
the Appendix. Left ventricular hypertrophy (LVH) was defined as
a left ventricular mass index (LVMI) higher than 131 g/m2 for men
and higher than 100 g/m2 for women.5
Definitions and Statistics
This report was based on the guidelines for reporting morbidity
and mortality after cardiac valvular operations.6 Survival and
time-related event analyses were performed with the Kaplan-Meier
method. Multivariable analyses of risk factors for survival and
time-related events were done by Cox regression methods previ-
ously described. The term actuarial survival was used to describe
time-related analysis for that event and not to describe the type of
analysis performed. Differences were tested for statistical signifi-
cance with 1-way analysis of variance. When the F test revealed a
significant difference, each pair of means was compared with the
Scheffe´ test.
Results
Patient Survival
There were 11 operative deaths (4%). Eight of the 11
patients (73%) had undergone combined AVR and coronary
artery bypass grafting. There were 58 late deaths (23%).
Thirty-five of the 58 patients (60%) had undergone com-
bined AVR and coronary artery bypass grafting. Operative
mortality and morbidity and late mortality are shown in
Table 3. The actuarial survival is shown in Figure 1. Mul-
tivariate analysis showed that preoperative New York Heart
Association (NYHA) functional class III or IV (odds ratio
TABLE 1. Clinical characteristics
No. of patients 254
Age (y, mean  SD) 71.3  8.8 (25-87)
Sex (No.)
Male 117 46%
Female 137 54%
Electrocardiogram (No.)
Sinus 226 89%
Atrial fibrillation 17 7%
Heart block 11 4%
NYHA functional classification
Class I 2 1%
Class II 36 14%
Class III 127 50%
Class IV 89 35%
Aortic valve lesion
Stenosis 155 61%
Insufficiency 35 14%
Mixed 64 25%
Mitral valve lesion
Stenosis 7 3%
Insufficiency 10 4%
Mixed 1 0.5%
Coronary artery disease
None 126 50%
1-Vessel 41 16%
2-Vessel 35 14%
3-Vessel 52 20%
Left ventricular function
 0.54 79 31%
0.40-0.54 111 44%
0.20-0.40 47 18%
 0.20 5 2%
Endocarditis 12 5%
Reoperation 36 14%
Previous AVR 27 11%
Previous coronary artery bypass grafting 15 6%
Previous mitral valve replacement 2 1%
Previous other 3 1%
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1.49, 95% confidence interval 1.02-2.18, P  .04) and the
presence of coronary artery disease (odds ratio 2.08, confi-
dence interval 1.26-3.44, P  .004) were independent risk
factors for late death.
Valve-Related and Cardiac-Related Deaths
The actuarial freedoms from valve-related death at 5, 10,
and 12 years were 98%  1%, 96%  2%, and 84% 
11%, respectively. The actuarial freedoms from cardiac
death at 5, 10, and 12 years were 87%  2%, 73%  7%,
and 73%  7%, respectively.
Complications
Thromboembolism. Thromboembolic events were ob-
served in 17 cases (14 strokes and 3 transient ischemic
attacks). The freedoms from thromboembolism at 5, 10, and
12 years were 93%  2%, 88%  3%, and 67%  13%,
respectively. The linearized rate for thromboembolic events
was 1.4%  0.1% events/100 patient-years. At the last
follow-up 38 of 178 patients (21%) were taking warfarin
sodium and 140 (79%) were taking aspirin daily. Multivar-
iate analysis showed that age (odds ratio 1.11, 95% confi-
dence interval 1.02-1.20, P  .01) was an independent risk
factor for thromboembolism.
Structural valve dysfunction. Structural valve deterio-
ration occurred in 4 patients, and they were reoperated on
after 8, 9, 9, and 13 years of follow-up. All 4 patients had
cusp tears: 2 had commissural tears and 2 had midcusp
tears. In addition, 3 patients had calcification of the cusps.
The actuarial freedoms from structural valve dysfunction at
5, 10, and 12 years were 100%, 86% 9%, and 86% 9%,
respectively (Figure 2). The actual freedoms from structural
valve dysfunction at the corresponding intervals were
100%, 92%  6%, and 92%  6%, respectively (Figure 2).
There were no valve failures in patients older than 65 years.
Bioprosthetic valve endocarditis. Five patients had bio-
prosthetic valve endocarditis that was diagnosed at 22 days,
4 months, 6 months, 3 years, and 3.5 years after the oper-
ation. Two patients were treated with antibiotics and re-
placement of the bioprosthesis, after which both survived.
Three patients were treated with antibiotics alone; 1 sur-
vived and 2 died. The patient who survived after treatment
with antibiotics alone had only mild aortic regurgitation on
echocardiography at follow-up. The actuarial freedoms
from bioprosthetic valve endocarditis at 5, 10, and 12 years
were 98%  1%, 98%  1%, and 98%  1%, respectively.
Reoperations. Six patients underwent reoperation, and
all survived. The indications for reoperation were structural
valve deterioration in 4 cases and endocarditis in 2 cases.
The actuarial freedoms from reoperation at 5, 10, and 12 years
were 99% 1%, 83%  9%, and 83%  9%, respectively.
Other complications. Only 1 patient had a serious anti-
coagulant-related hemorrhage, even though 21% of the pa-
tients were receiving oral anticoagulation. Four patients
needed late pacemaker implantation. Eight patients had a
late acute myocardial infarction.
TABLE 2. Operative data
No. of patients 254
Valve sizes implanted (mm, mean  SD) 22.4 2.3 (19-29)
19 mm (no.) 13 5%
21 mm (no.) 101 40%
23 mm (no.) 85 33.5%
25 mm (no.) 46 18%
27 mm (no.) 8 3%
29 mm (no.) 1 0.5%
Associated procedures
Coronary artery bypass grafting 130 51%
Mitral valve replacement 11 4%
Mitral valve repair 10 4%
Tricuspid valve repair 4 1.5%
Miscellaneous 11 4%
Aortic crossclamp time
(min, mean  SD)
86.5 31.0 (45-236)
Cardiopulmonary bypass time (min,
mean  SD)
118.4 43.1 (61-335)
TABLE 3. Operative morbidity and mortality and late mor-
tality
No. %
Operative morbidity
Reexploration for bleeding 15 6
Reexploration for cardiac arrest 2 1
Perioperative myocardial infarction 7 3
Perioperative stroke or transient ischemic attack 10 4
Mediastinitis 4 2
Permanent pacemaker implantation 16 6
Operative mortality 11 4
Cardiac arrest 2
Low cardiac output syndrome 5
Sepsis 2
Multiple organ failure 1
Other 1
Late mortality 58 23
Valve related 5
Stroke 3
Endocarditis 2
Cardiac related 24
Congestive heart failure 6
Myocardial infarction 10
Sudden death 5
Other 3
Noncardiac 26
Unknown 3
Total early and late deaths 69/254 27
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Late Functional Classification
At the latest follow-up 178 patients were alive and had the
original CEP bioprosthesis in place. Seventy-two patients
(41%) were in NYHA functional class I, 63 (35.5%) were in
class II, 41 (23%) were in class III, and 1 (0.5%) was in
class IV.
Echocardiography
Echocardiography of long-term survivors (mean 67  25
months) showed that peak and mean gradients for all valve
sizes were 23.2  9.6 mm Hg (range 11-66 mm Hg) and
12.3 4.8 mm Hg (range 5-31 mm Hg), respectively. Table
4 shows Doppler-echocardiographic data according to valve
sizes at late follow-up. Smaller valves had statistically sig-
nificantly higher transvalvular peak (P  .02) and mean
(P  .003) gradients than did larger valves. Mean aortic
valve area for all valves was 1.3 0.3 (range 0.5-2.36 cm2),
and area increased significantly with increasing valve size
(P  .0001). Also, aortic valve areas were significantly
larger in 27-, 25-, and 23-mm valves than in 19- and 21-mm
valves (Table 4). However, 22 patients (20%) had an aortic
valve area smaller than 1 cm2 at late follow-up.
Figure 2. Actuarial (circles) and actual (squares) freedoms from structural valve degeneration (SVD).
Figure 1. Actuarial survival. Data points represent mean; error bars represent SEM.
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M-mode Doppler measurements and calculations of left
ventricular mass and LVMI are shown in Table 5. In a
general linear model there were significant increases in left
ventricular end-diastolic dimension (P  .03) and interven-
tricular septum (P  .04) with increasing valve size. How-
ever, there was no significant difference in posterior wall
measurement (P .42) with increasing valve size. The only
statistically significant difference seen between valve sizes
was that left ventricular end-diastolic dimension was in-
creased in patients with 25-mm valves relative to those with
21-mm valves (Table 5). Mean left ventricular mass and
LVMI were 189.0  70.5 g (range 90-518 g) and 107.2 
35.3 g/m2 (range 53-245 g/m2, male 118.9  40.2 g/m2,
female 98.8  28.8 g/m2), respectively. Left ventricular
mass and LVMI increased statistically significantly with
increasing valve size (P .0001 and P .01, respectively).
Body surface area also increased significantly with in-
creased valve size (P  .0001). One third of all patients,
regardless of gender (26/64 of the women and 14/45 of the
men), had evidence of LVH. Valve sizes correlated for body
surface area (indexed valve size) in patients with LVH were
similar to those in patients without LVH (Figure 3). This
suggests that valve mismatch was not the reason for LVH
seen at long-term follow-up in this subgroup of patients.
Indexed valve area stratified according to valve size showed
a trend toward higher mean indexed valve sizes for larger
valves, which might suggest a relative mismatch for smaller
valve sizes (Figure 4). However, LVMI increased with
larger valve sizes, again indicating that valve size or valve
mismatch was not the final determinant of LVMI or LVH.
At follow-up, 69% (n  75/109) had normal systolic left
ventricular function, whereas 25% (n  28/109) of the
patients had mildly impaired left ventricular function, 3%
(n  3/109) had moderately impaired left ventricular func-
tion, and 3% (n  3/109) had severely impaired left ven-
tricular function.
None or trivial, mild, moderate, and severe aortic insuf-
ficiencies were found in 65% (n  71/109), 31% (n 
34/109), 3% (n  3/109), and 1% (n  1/109) of the
patients, respectively. Mitral regurgitation at follow-up was
none or trivial in 28% of the patients (n  31/109), mild in
49% (n  53/109), moderate in 19% (n  21/109), and
severe in 4% (n  4/109). There was no significant differ-
ence in mitral regurgitation between patients with and with-
out preoperative coronary artery disease (P  .3). Further-
more, when patients were stratified according to both
preoperative aortic insufficiency and mitral regurgitation at
follow-up, there was no significant difference in LVMI
between groups (Figure 5). However, a trend toward higher
LVMI was seen in patients with preoperative aortic insuf-
ficiency and more than mild mitral regurgitation at fol-
low-up echocardiography.
Discussion
The use of glutaraldehyde-treated bovine pericardial valves
for AVR was introduced in 1971 by Ionescu and associ-
ates.7 Those valves were at the time superior to porcine
valves from a hemodynamic point of view8 but showed
signs of limited durability in fatigue tests, a problem that
was later confirmed clinically.9,10 The CEP aortic valve was
introduced after several design changes, which included
improved tissue preservation, a more flexible stent, a mod-
ified shape of the cusps, and modified tissue-mounting of
the pericardium in the stent. Early clinical and hemody-
namic studies showed excellent results.11,12 Several studies
have shown excellent long-term durability with CEP
valves,1-4 which seems to be related to a lower risk of
primary tissue failure than seen with older porcine and
bovine pericardial valves.
In this report of clinical and hemodynamic late outcomes
after AVR with the CEP bioprosthesis, we confirm previous
studies indicating good results comparable to newer porcine
TABLE 4. Doppler echocardiographic results of CEP aortic valve bioprosthesis according to valve size at follow-up
Valve
size
(mm) No. of patients Ppeak (mm Hg) Pmean (mm Hg) EOA (cm
2) CI (L  min1  m2) BSA (m2)
19 5 38.4 17.4 19.4 7.6 0.95 0.2 3.5 1.2 1.59 0.1
21 45 24.7 10.2 13.0 5.0 1.1 0.2 2.7 0.5 1.66 0.2
23 33 21.4 7.2 11.2 3.6* 1.5 0.3†‡ 2.6 0.9 1.82 0.1‡
25 22 20.1 7.3§ 11.2 4.3* 1.4 0.3†‡ 2.4 0.7 1.87 0.2‡
27 4 19.0 10.8 10.1 4.5 1.6 0.4† 2.5 0.8 1.84 0.14
All sizes 109 23.2 9.6 12.3 4.8 1.3 0.3 2.7 0.7 1.76 0.2
All values are expressed as mean  SD. Significant differences between valve sizes according to Scheffe´ test are indicated by symbols. Ppeak, Maximum
pressure difference; Pmean, mean pressure difference; EOA, effective orifice area, CI, cardiac index; BSA, body surface area.
*P  .05, sizes 25 and 23 versus size 19 mm.
†P  .05, sizes 27, 25, and 23 versus size 19 mm.
‡P  .05, sizes 25 and 23 versus size 21 mm.
§P  .05, size 25 versus size 19 mm.
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valves.2,3,13 Banbury and associates2 and Neville and asso-
ciates4 reported similar 5- and 10-year survivals, although in
somewhat younger patient populations than in our study, for
the CEP bioprosthesis in the aortic position. Table 6 shows
survivals and freedoms from structural valve degeneration
in earlier reported studies of the CEP pericardial biopros-
thesis. Poirier and coworkers3 have reported excellent sur-
vival rates in a younger patient population than ours. Sur-
vivals for our patient population with the CEP bioprosthesis
were lower than in our population with the Hancock II
porcine bioprosthesis.13 However, our patients with the CEP
bioprosthesis were significantly older than those with the
Hancock II porcine bioprosthesis (Table 6). We have pre-
viously shown that advanced age, male sex, advanced left
ventricular dysfunction, coronary artery disease, and ad-
vanced NYHA functional class are independent predictors
of mortality among patients with AVR.14 Our patient pop-
ulation was in general older and had more coronary artery
disease than in other studies.1-4,11,13 Considering the risk
factor profile in our study, the survival must be considered
satisfactory. As anticipated, the multivariate analysis from
our study showed that coronary artery disease and NYHA
class III or IV were risk factors for late death and for cardiac
non-valve-related death.
Our study confirms that the CEP bioprosthesis is associ-
ated with a low incidence of structural valve dysfunction
comparable to earlier reports1-4 (Table 6). In our population,
no patient older than 65 years has required reoperation
because of structural valve degeneration. Some authors
have even indicated that the CEP bioprosthesis may be
superior to stented porcine bioprostheses in terms of struc-
tural valve dysfunction.2 When the CEP valve is compared
with the Hancock II, a second-generation porcine aortic
valve, however, the risk of degeneration appears to be
TABLE 5. M-mode echocardiographic results and calculations of CEP aortic valve bioprosthesis according to valve size
at follow-up
Valve size (mm) No. of patients LVEDD (mm) IVS (mm) PW (mm) LVM (g) LVMI (g/m2) LVH (No.)
19 5 41.0 10.9 13.1 1.9 10.5 1.5 166.6 69.7 103.2 35.5 2 (40%)
21 45 42.1 6.0 11.6 2.6 10.3 2.2 161.1 51.8 97.0 29.4 14 (31%)
23 33 45.6 5.9 12.6 2.2 10.4 1.8 192.2 53.7 105.7 28.0 11 (33%)
25 22 49.1 9.4* 13.7 3.3 11.1 1.9 243.4 94.2* 129.7 46.0* 11 (50%)
27 4 44.4 3.6 13.8 3.8 11.8 1.7 219.2 76.1 119.7 43.1 2 (50%)
All sizes 109 44.6 7.4 12.5 2.7 10.5 2.0 189.0 70.5 107.2 35.3 40 (37%)
All values are expressed as mean  SD. (Significant differences between valve sizes according to Scheffe´ test are indicated by symbols.) LVEDD, Left
ventricular end-diastolic dimension; IVS, interventricular septum; PW, posterior wall; LVM, left ventricular mass; LVMI, left ventricular mass index; LVH, left
ventricular hypertrophy.
*P  .05, size 25 versus size 21 mm.
Figure 3. Valve size indexed to body surface area (BSA) and LVMI stratified for patients with (squares) and without
(circles) LVH.
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similar. In our experience the Hancock II was used in a
younger patient population, and the freedom from valve
degeneration was similar to that of the CEP valve. The
clinical and hemodynamic data of the CEP and Hancock II
valves are similar according to our experience.15 Transval-
vular gradients and aortic valve areas for the CEP appear to
be slightly worse than those of the Hancock II according to
retrospective studies. However, neither of these valves has
as good hemodynamic data as the Toronto SPV or the
Freestyle bioprosthesis.16,17 There are a few long-term re-
ports with echocardiography on the CEP. Frater and co-
workers11 reported aortic valve areas somewhat similar to
those found in our study after a mean follow-up of 67
months.
We found that LVH was still present at long-term fol-
low-up in about a third of the patients. In contrast, as
previously reported by our group,16 only 8% of the patients
with a Toronto SPV had LVH by echocardiography after a
similar mean follow-up of 5 years. However, we have also
showed that sex, hypertension, cause of valve disease, and
presence of coronary artery disease,16 as well as genetic
factors,18 influence both the preoperative degree of LVH
Figure 5. LVMI stratified for preoperative aortic insufficiency (AI) and mitral regurgitation (MR) on follow-up
echocardiogram. Dark bars, Aortic insufficiency value of 1; light bars, aortic insufficiency value of 0.
Figure 4. Mean valve size indexed to body surface area (BSA) for all aortic valve sizes. Darkest shading, 27 mm;
second darkest, 21 mm; median shading, 19 mm; second lightest, 25 mm; lightest, 23 mm.
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and its regression. Thus many confounding factors exists
between the previously mentioned studies, which makes it
difficult to safely conclude anything regarding the degree of
LVH at late follow-up. Maybe the most surprising finding of
the late follow-up echocardiography was that 23% of the
patients had moderate or severe mitral regurgitation. How-
ever, we were not able to show that either mitral regurgita-
tion or preoperative aortic insufficiency was significantly
more common among patients with LVH than among those
without LVH.
Limitations of the Study
This study was retrospective, and therefore the valve-related
complication rates were probably underestimated because
follow-up was only obtained once for this population. How-
ever, the follow-up was 100% complete and reliable with
respect to survival, reoperation, and echocardiographic data.
The last, however, must be interpreted with caution, because
the analysis was performed retrospectively and only in-
cluded about 60% of the population who were alive at the
time of the study.
We are grateful to Drs C.M. Feindel, R.D. Weisel, H.E. Scully,
C.M. Peniston, B.S. Goldman, R.J. Baird, and L.L. Mickelborough
for allowing us to use their patients’ data for this study.
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Appendix
Doppler Echocardiography
Color flow Doppler echocardiography was used to assess aortic
insufficiency in the parasternal long-and short-axis views and in
the apical 5- and 3-chamber views. Two-dimensional guided and
TABLE 6. Survival and structural valve degeneration data for CEP bioprosthesis
Reference
No. of
patients Mean age (y)
Survival
Freedom from structural valve
degeneration
5 y 10 y 12 y 5 y 10 y 12 y
Pericardial (Carpentier-Edwards)
Pellerin et al,1 1995 124 64.9 13.6 50% 7% 100% 100% 100%
Banbury et al,2 1998 310 64.2 10.8 83% 2% 47% 3% 34% 3% 100% 91% 3% 82% 4%
Poirier et al,3 1998 812 64 80% 2% 69% 3% 68% 3% 99% 0.5% 93% 2% 80% 5%
Neville et al,4 1998 787 68.3 10.8 53% 0.5% 99% 1% 94% 4% 94% 4%
Current study 254 71.3 8.8 80% 3% 50% 8% 36% 9% 100% 86% 9% 86% 9%
Porcine (Hancock II)
David et al,13 1998 723 65 12 79% 2% 61% 3% 54% 4% 100% 97% 1% 94% 2%
Data are mean  SD when available.
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stand-alone continuous-wave Doppler modes were used to inter-
rogate flow through the aortic valve from multiple positions.
Pulsed-wave Doppler was used to assess flow in the left ventricular
outflow tract (LVOT).
The peak (VAVmax) and mean (VAVmean) systolic flow velocities
(in meters per second) across the aortic valve were recorded with
continuous-wave Doppler, and those proximal to the aortic valve
in the LVOT (VLVOTmax and VLVOTmean) were recorded with pulsed-
wave Doppler. The average of three consecutive cardiac cycles in
sinus rhythm or of 10 cardiac cycles in atrial fibrillation was used
to calculate transaortic velocities and velocity time integrals
(VTIAV and VTILVOT , in centimeters). Peak (PLVOTpeak and PAVpeak)
and mean (PAVmean and PLVOTmean) pressure differences (in milli-
meters of mercury) were calculated according to the modified
Bernoulli equation1:
Ppeak  4  (VAVmax2 - VLVOTmax2)
Pmean  PAVmean  PLVOTmean
PAVmean  PLVOTmean  4  (VAVmean2  VLVOTmean2)
The LVOT diameter (D, in centimeters) was determined in
midsystole from the parasternal long-axis view. The effective
orifice area (EOA, in centimeters) was calculated with the conti-
nuity equation1:
EOA (cm2)  3.14  2D/4  VTILVOT/VTIAV
Cardiac output (CO, in liters per minute) was calculated as the
product of stroke volume and heart rate (HR, in beats/min)1:
CO  HR  (3.14  2D/4  VTILVOT)/1000
Measurements of interventricular septum (IVS) and posterior
wall (PW) thicknesses (in centimeters) and left ventricular end-
diastolic dimension (LVEDD, in centimeters) were obtained with
2-dimensional echocardiography in a standard fashion. Left ven-
tricular mass (LVM, in grams) was calculated from IVS and PW
thicknesses and the LVEDD according to the American Society of
Echocardiography cube method2:
LVM  0.8  1.04  [(IVS  PW  LVEDD)3
 (LVEDD)3]  0.6
The left ventricular mass index was calculated by dividing
LVM by body surface area.
Aortic insufficiency was assessed with color flow Doppler and
CW and PW Doppler in any view.3 The ejection fraction was
determined according to the Simpson rule and left ventricular
function was classified by ejection fraction as grade 1 (60%),
grade 2 (40%-60%), grade 3 (20%-40%), or grade 4 (20%).1
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